An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

Nature Communications

Volumn 8, Issue , 2017, Pages

  Vallejo, Adrian ^a   Perurena, Naiara ^a   Guruceaga, Elisabet ^a   Mazur, Pawel K ^b   Martinez Canarias, Susana ^a   Zandueta, Carolina ^a   Valencia, Karmele ^a   Arricibita, Andrea ^a   Gwinn, Dana ^b   Sayles, Leanne C ^b   Chuang, Chen Hua ^b   Guembe, Laura ^a   Bailey, Peter ^c   Chang, David K ^c,d,e,f,g   Biankin, Andrew ^c,d,e,f,g   Ponz Sarvise, Mariano ^a,h   Andersen, Jesper B ⁱ   Khatri, Purvesh ^b,j   Bozec, Aline ^k   Sweet Cordero, E Alejandro ^b   Sage, Julien ^b   Lecanda, Fernando ^a,l,m   Vicent, Silve ^a,l,m   more..

^a UNIVERSITY OF NAVARRA   (Spain)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j STANFORD UNIVERSITY   (United States)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l IdiSNA Navarra Institute for Health Research   (Spain)

^m UNIVERSITY OF NAVARRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; AMPHIREGULIN; AURORA A KINASE; CYCLIN B1; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; DUAL SPECIFICITY PHOSPHATASE 6; FORKHEAD BOX PROTEIN M1; HURP PROTEIN; LAMB3 PROTEIN; LAMC2 PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PEPTIDES AND PROTEINS; PHLDA1 PROTEIN; PROTEIN; SPRY4 PROTEIN; TACC3 PROTEIN; TRAMETINIB; TRANSCRIPTION FACTOR FRA 1; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; PROTEIN C FOS; PROTEIN P21;

CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; HOMINID; INHIBITION; INTEGRATED APPROACH; SURVIVAL; TUMOR; VULNERABILITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; META ANALYSIS (TOPIC); MOUSE; MUTANT; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; SURVIVAL ANALYSIS; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; MUTATION; NUDE MOUSE; ONCOGENE; PANCREAS TUMOR; PROCEDURES; RNA INTERFERENCE; RNAI THERAPEUTICS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; MUTATION; ONCOGENES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE; RNAI THERAPEUTICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013453512     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14294     Document Type: Article

References (70)

1. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774 (2011).
2. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
3. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
4. Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600-608 (2008).
5. O'Dell, M. R. et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 72, 1557-1567 (2012).
6. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262 (2001).
7. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
8. Bollag, G. & Zhang, C. Drug discovery: pocket of opportunity. Nature 503, 475-476 (2013).
9. Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37, 48-55 (2005).
10. Arena, S. et al. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res. 67, 8468-8476 (2007).
11. Singh, A. et al. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500 (2009).
12. Tchernitsa, O. I. et al. Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene 23, 4536-4555 (2004).
13. Schulze, A., Nicke, B., Warne, P. H., Tomlinson, S. & Downward, J. The transcriptional response to Raf activation is almost completely dependent on mitogen-activated protein kinase kinase activity and shows a major autocrine component. Mol. Biol. Cell 15, 3450-3463 (2004).
14. Stelniec-Klotz, I. et al. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol. Syst. Biol. 8, 601 (2012).
15. Vicent, S. et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J. Clin. Invest. 120, 3940-3952 (2010).
16. Wang, I. C. et al. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.). Oncogene 33, 5391-5396 (2013).
17. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683 (2008).
18. Mazur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. 21, 1163-1171 (2015).
19. Young, M. R. et al. Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol. Cell Biol. 22, 587-598 (2002).
20. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
21. Steckel, M. et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22, 1227-1245 (2012).
22. Downward, J. RAS synthetic lethal screens revisited: still seeking the elusive prize? Clin. Cancer Res. 21, 1802-1809 (2015).
23. Sweet-Cordero, A. et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 45, 338-348 (2006).
24. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
25. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47-52 (2016).
26. Young, M. R. & Colburn, N. H. Fra-1 a target for cancer prevention or intervention. Gene 379, 1-11 (2006).
27. Mechta, F., Lallemand, D., Pfarr, C. M. & Yaniv, M. Transformation by ras modifies AP1 composition and activity. Oncogene 14, 837-847 (1997).
28. Kakumoto, K. et al. FRA1 is a determinant for the difference in RAS-induced transformation between human and rat fibroblasts. Proc. Natl Acad. Sci USA 103, 5490-5495 (2006).
29. Vial, E., Sahai, E. & Marshall, C. J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4, 67-79 (2003).
30. Tuveson, D. A. et al. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
31. Larrayoz, M. et al. Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Mol. Med. 6, 539-550 (2014).
32. Winslow, M. M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101-104 (2011).
33. Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302 (2007).
34. Means, A. L. et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 132, 3767-3776 (2005).
35. Patra, K. C. et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24, 213-228 (2013).
36. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
37. Lefebvre, C. et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 6, 377 (2010).
38. Laoukili, J. et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 7, 126-136 (2005).
39. Wonsey, D. R. & Follettie, M. T. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 65, 5181-5189 (2005).
40. Lens, S. M., Voest, E. E. & Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10, 825-841 (2010).
41. Burgess, S. G. et al. Aurora-A-dependent control of TACC3 influences the rate of mitotic spindle assembly. PLoS Genet. 11, e1005345 (2015).
42. Burrell, R. A. & Swanton, C. The evolution of the unstable cancer genome. Curr. Opin. Genet. Dev. 24, 61-67 (2014).
43. Ambrogio, C. et al. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat. Med. 22, 270-277 (2016).
44. Doehn, U. et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol. Cell 35, 511-522 (2009).
45. Fukushige, S. et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19, 161-169 (1997).
46. Li, D. et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. 9, 991-997 (2003).
47. Patel, A. V. et al. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin. Cancer Res. 18, 5020-5030 (2012).
48. Lim, K. H. et al. Aurora - A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol. Cell Biol. 30, 508-523 (2010).
49. Wu, J. C. et al. Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J. Biol. Chem. 280, 9013-9022 (2005).
50. Manchado, E. et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534, 647-651 (2016).
51. Wang, J. et al. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat. Commun. 7, 11363 (2016).
52. Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498-504 (2009).
53. Eferl, R. et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 23, 2789-2799 (2004).
54. Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005).
55. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).
56. Zheng, Y. et al. A rare population of CD24+ITGB4+Notchhi cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 24, 59-74 (2013).
57. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).
58. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
59. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article 3 (2004).
60. Chitale, D. et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28, 2773-2783 (2009).
61. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
62. Blake, J. A. et al. Gene Ontology annotations and resources. Nucleic Acids Res. 41, D530-D535 (2013).
63. Chen, R. et al. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res. 74, 2892-2902 (2014).
64. Hastie, T., Tibshirani, R. & Friedman, J. The Elements of Statistical Learning: Prediction, Inference and Data Mining (Springer Verlag, 2001).
65. Bhattacharjee, A. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98, 13790-13795 (2001).
66. Vicent, S. et al. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 72, 5744-5756 (2012).
67. Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. ROCR: visualizing classifier performance in R. Bioinformatics 21, 3940-3941 (2005).
68. Nguyen, D. X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51-62 (2009).
69. Clark, T. G., Bradburn, M. J., Love, S. B. & Altman, D. G. Survival analysis part I: basic concepts and first analyses. Br. J. Cancer 89, 232-238 (2003).
70. Bradburn, M. J., Clark, T. G., Love, S. B. & Altman, D. G. Survival analysis part II: multivariate data analysis - An introduction to concepts and methods. Br. J. Cancer 89, 431-436 (2003).